In several animal models, recombinant TPO was administered after bone marrow infusion with no significant effect on the recovery of any lineage. These unexpected results led to further investigations in mice in which the donor animals were treated with recombinant TPO, and the TPO-stimulated marrow was transplanted into recipient animals (Fig. 9). This TPO-stimulated marrow transplantation reduced the duration of thrombocytopenia and allowed earlier recovery of erythrocytes (93). It may be more important to use TPO to treat the stem cell donor than to treat the stem cell recipient, a conclusion also reached in human trials (94).
Was this article helpful?